Overview

This trial is active, not recruiting.

Conditions anaplastic large cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent mantle cell lymphoma
Treatments belinostat, rituximab, yttrium y 90 ibritumomab tiuxetan
Phase phase 2
Targets HDAC, CD20
Sponsor University of Arizona
Collaborator National Cancer Institute (NCI)
Start date June 2012
End date February 2016
Trial size 5 participants
Trial identifier NCT01686165, 12-0288-04, 1200000288, NCI-2012-01131, P30CA023074

Summary

This study looks at what effects (good and bad) a drug called PXD-101 (belinostat) in combination with the radioactive drug Zevalin (yttrium Y 90 ibritumomab tiuxetan) has on patients with relapsed aggressive (high-risk) non-Hodgkin lymphoma. Studies in the laboratory suggest that drugs such as PXD101 can act upon specific cancer cell processes to cause either death of the cancer cells or prevention of their growth. In human studies with a small number of patients with this lymphoma, PXD-101 has shown the ability to shrink and slow tumor growth. When Zevalin is delivered directly to the tumor, the lymphoma cells are destroyed and this may result in the disappearance of the tumor (remission)

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
belinostat PXD101
Given IV
rituximab IDEC-C2B8
Given IV
yttrium y 90 ibritumomab tiuxetan 90Y ibritumomab tiuxetan
Given IV

Primary Outcomes

Measure
Complete response rate
time frame: Up to 5 years
Overall response
time frame: Up to 5 years

Secondary Outcomes

Measure
Progression-free survival
time frame: 2 years
Occurrence of adverse events and serious adverse events
time frame: Up to 30 days after patient receives last dose of study drug

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Biopsy confirmed, CD20 positive diffuse large B-cell lymphoma, primary mediastinal b-cell lymphoma, mantel cell lymphoma, transformed indolent lymphoma, high grade-B-cell lymphoma; AND bone marrow must show =< 20% CD20+ B-cells with >= 15% cellularity within 42 days of study registration - Any stage disease - Patients must have been previously treated: - >= 3rd line if bone marrow transplant (BMT) candidate OR - >= 2nd line if not BMT candidate OR - >= 2nd relapse for BMT candidate OR - >= 1st relapse for non- BMT candidate - Must have a diagnostic quality CT scan of the chest, abdomen and pelvis OR baseline PET-CT scan performed within 28 days prior to registration - Must have bidimensionally measurable disease with lesions at least 1.5 cm in one dimension ALL measurable disease must be assessed within 28 days of registration - To determine prior drug regimens: radiation therapy counts as 1 treatment, BMT including induction counts as one treatment, radioimmunotherapy is not considered a chemotherapy regimen, rituximab alone is not considered a treatment; all prior therapy must have been completed at least 30 days prior to registration; patients should not have taken valproic acid, or any other histone deacetylase inhibitor (eg., vorinostat, romidepsin), for at least 30 days prior to registration; patients must have recovered from any toxicities related to therapies prior to registration - No clinical evidence of CNS involvement by lymphoma, any lab (eg., LDH or radiographic tests performed to access CNS involvement must be negative and must be performed within 42 days prior to registration - Unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration - Life expectancy of greater than 3 months - Karnofsky performance status >= 60% - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - AST (SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal - Total bilirubin =< 1.5 X institutional upper limit of normal (unless associated with Gilbert's syndrome) - Serum creatinine < 2 x institutional upper limit of normal OR - Measured creatinine clearance >= 60 mL/min - LDH < 1.50 X institutional upper limit of normal - EKG with no significant abnormalities within 28 days prior to registration - Women of child-bearing potential and men must agree to use adequate contraception Exclusion Criteria: - Patients who have had chemotherapy or radiotherapy within 30 days (6 weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier - Prior radioimmunotherapy - Pregnant or nursing - Clinical evidence of CNS involvement by lymphoma - History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study - Concomitant medication that may cause Torsade de Pointes, i.e. prolongation of the QT interval > 500 msec - Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure related to primary cardiac disease, any condition requiring anti-arrhythmic therapy, ischemic or valvular heart disease, or a myocardial infarction within the past 6 months - Current long QT syndrome or baseline prolongation of QT/QTcF interval, i.e. demonstration of a QTcF interval > 450 msec - Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening - Known to be human immunodeficiency virus (HIV) positive or with known acquired immunodeficiency syndrome (AIDS) syndrome - Patients may not be receiving any other investigational agents

Additional Information

Official title A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma
Principal investigator Soham Puvvada
Description PRIMARY OBJECTIVES: I. To document the complete response rate and overall response for patients with relapsed aggressive high-risk non-Hodgkin's lymphoma treated with two cycles PXD-101 followed by one cycle of Zevalin. SECONDARY OBJECTIVES: I. To estimate 2-year progression-free survival in patients with relapsed aggressive high-risk non-Hodgkin's lymphoma treated with two cycles PXD-101 followed by one cycle of Zevalin. II. To evaluate the toxicity of two cycles PXD-101 and one cycle of Zevalin in patients with relapsed aggressive high-risk non-Hodgkin's lymphoma. OUTLINE: Patients receive belinostat intravenously (IV) over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Arizona.